264 related articles for article (PubMed ID: 38745767)
1. Tumor metabolism in pheochromocytomas: clinical and therapeutic implications.
Jeeyavudeen MS; Mathiyalagan N; Fernandez James C; Pappachan JM
Explor Target Antitumor Ther; 2024; 5(2):349-373. PubMed ID: 38745767
[TBL] [Abstract][Full Text] [Related]
2. The connection between tricarboxylic acid cycle enzyme mutations and pseudohypoxic signaling in pheochromocytoma and paraganglioma.
Wang Y; Liu B; Li F; Zhang Y; Gao X; Wang Y; Zhou H
Front Endocrinol (Lausanne); 2023; 14():1274239. PubMed ID: 37867526
[TBL] [Abstract][Full Text] [Related]
3. Krebs cycle metabolite profiling for identification and stratification of pheochromocytomas/paragangliomas due to succinate dehydrogenase deficiency.
Richter S; Peitzsch M; Rapizzi E; Lenders JW; Qin N; de Cubas AA; Schiavi F; Rao JU; Beuschlein F; Quinkler M; Timmers HJ; Opocher G; Mannelli M; Pacak K; Robledo M; Eisenhofer G
J Clin Endocrinol Metab; 2014 Oct; 99(10):3903-11. PubMed ID: 25014000
[TBL] [Abstract][Full Text] [Related]
4. Metabolome-guided genomics to identify pathogenic variants in isocitrate dehydrogenase, fumarate hydratase, and succinate dehydrogenase genes in pheochromocytoma and paraganglioma.
Richter S; Gieldon L; Pang Y; Peitzsch M; Huynh T; Leton R; Viana B; Ercolino T; Mangelis A; Rapizzi E; Menschikowski M; Aust D; Kroiss M; Beuschlein F; Gudziol V; Timmers HJ; Lenders J; Mannelli M; Cascon A; Pacak K; Robledo M; Eisenhofer G; Klink B
Genet Med; 2019 Mar; 21(3):705-717. PubMed ID: 30050099
[TBL] [Abstract][Full Text] [Related]
5. The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma.
Peng S; Zhang J; Tan X; Huang Y; Xu J; Silk N; Zhang D; Liu Q; Jiang J
Front Endocrinol (Lausanne); 2020; 11():586857. PubMed ID: 33329393
[TBL] [Abstract][Full Text] [Related]
6. Correlation between in vivo 18F-FDG PET and immunohistochemical markers of glucose uptake and metabolism in pheochromocytoma and paraganglioma.
van Berkel A; Rao JU; Kusters B; Demir T; Visser E; Mensenkamp AR; van der Laak JA; Oosterwijk E; Lenders JW; Sweep FC; Wevers RA; Hermus AR; Langenhuijsen JF; Kunst DP; Pacak K; Gotthardt M; Timmers HJ
J Nucl Med; 2014 Aug; 55(8):1253-9. PubMed ID: 24925884
[TBL] [Abstract][Full Text] [Related]
7. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
8. Succinate Mediates Tumorigenic Effects
Matlac DM; Hadrava Vanova K; Bechmann N; Richter S; Folberth J; Ghayee HK; Ge GB; Abunimer L; Wesley R; Aherrahrou R; Dona M; Martínez-Montes ÁM; Calsina B; Merino MJ; Schwaninger M; Deen PMT; Zhuang Z; Neuzil J; Pacak K; Lehnert H; Fliedner SMJ
Front Endocrinol (Lausanne); 2021; 12():589451. PubMed ID: 33776908
[TBL] [Abstract][Full Text] [Related]
9. Significance of Alpha-inhibin Expression in Pheochromocytomas and Paragangliomas.
Mete O; Pakbaz S; Lerario AM; Giordano TJ; Asa SL
Am J Surg Pathol; 2021 Sep; 45(9):1264-1273. PubMed ID: 33826547
[TBL] [Abstract][Full Text] [Related]
10. Metabolomics in paraganglioma: applications and perspectives from genetics to therapy.
Richter S; Garrett TJ; Bechmann N; Clifton-Bligh RJ; Ghayee HK
Endocr Relat Cancer; 2023 Jun; 30(6):. PubMed ID: 36897220
[TBL] [Abstract][Full Text] [Related]
11. New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas.
Toledo RA
Endocr Relat Cancer; 2017 Sep; 24(9):C9-C19. PubMed ID: 28667082
[TBL] [Abstract][Full Text] [Related]
12. PHEOCHROMOCYTOMA: A GENETIC AND DIAGNOSTIC UPDATE.
Mercado-Asis LB; Wolf KI; Jochmanova I; Taïeb D
Endocr Pract; 2018 Jan; 24(1):78-90. PubMed ID: 29144820
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
14. Genetics and imaging of pheochromocytomas and paragangliomas: current update.
Katabathina VS; Rajebi H; Chen M; Restrepo CS; Salman U; Vikram R; Menias CO; Prasad SR
Abdom Radiol (NY); 2020 Apr; 45(4):928-944. PubMed ID: 31069476
[TBL] [Abstract][Full Text] [Related]
15. The Immune Landscape of Pheochromocytoma and Paraganglioma: Current Advances and Perspectives.
Uher O; Hadrava Vanova K; Taieb D; Calsina B; Robledo M; Clifton-Bligh R; Pacak K
Endocr Rev; 2024 Feb; ():. PubMed ID: 38377172
[TBL] [Abstract][Full Text] [Related]
16. GIPC2 is an endocrine-specific tumor suppressor gene for both sporadic and hereditary tumors of RET- and SDHB-, but not VHL-associated clusters of pheochromocytoma/paraganglioma.
Dong Y; Huang Y; Fan C; Wang L; Zhang R; Li W; Guo Z; Wang D; Zheng Z
Cell Death Dis; 2021 May; 12(5):444. PubMed ID: 33947839
[TBL] [Abstract][Full Text] [Related]
17. Metabolomics, machine learning and immunohistochemistry to predict succinate dehydrogenase mutational status in phaeochromocytomas and paragangliomas.
Wallace PW; Conrad C; Brückmann S; Pang Y; Caleiras E; Murakami M; Korpershoek E; Zhuang Z; Rapizzi E; Kroiss M; Gudziol V; Timmers HJ; Mannelli M; Pietzsch J; Beuschlein F; Pacak K; Robledo M; Klink B; Peitzsch M; Gill AJ; Tischler AS; de Krijger RR; Papathomas T; Aust D; Eisenhofer G; Richter S
J Pathol; 2020 Aug; 251(4):378-387. PubMed ID: 32462735
[TBL] [Abstract][Full Text] [Related]
18. Metabolome profiling by HRMAS NMR spectroscopy of pheochromocytomas and paragangliomas detects SDH deficiency: clinical and pathophysiological implications.
Imperiale A; Moussallieh FM; Roche P; Battini S; Cicek AE; Sebag F; Brunaud L; Barlier A; Elbayed K; Loundou A; Bachellier P; Goichot B; Stratakis CA; Pacak K; Namer IJ; Taïeb D
Neoplasia; 2015 Jan; 17(1):55-65. PubMed ID: 25622899
[TBL] [Abstract][Full Text] [Related]
19. Metabolomic Urine Profile: Searching for New Biomarkers of SDHx-Associated Pheochromocytomas and Paragangliomas.
Martins RG; Gonçalves LG; Cunha N; Bugalho MJ
J Clin Endocrinol Metab; 2019 Nov; 104(11):5467-5477. PubMed ID: 31504671
[TBL] [Abstract][Full Text] [Related]
20. Genetic and epigenetic differences of benign and malignant pheochromocytomas and paragangliomas (PPGLs).
Khatami F; Mohammadamoli M; Tavangar SM
Endocr Regul; 2018 Jan; 52(1):41-54. PubMed ID: 29453919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
